Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.

Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA.

Mol Cell Biol. 2013 Nov;33(22):4422-33. doi: 10.1128/MCB.00706-13.

2.

FBXO4 loss facilitates carcinogen induced papilloma development in mice.

Lian Z, Lee EK, Bass AJ, Wong KK, Klein-Szanto AJ, Rustgi AK, Diehl JA.

Cancer Biol Ther. 2015;16(5):750-5. doi: 10.1080/15384047.2015.1026512.

3.

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL.

Mol Cancer Ther. 2008 Sep;7(9):2876-83. doi: 10.1158/1535-7163.MCT-08-0431.

4.

Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation.

Kanie T, Onoyama I, Matsumoto A, Yamada M, Nakatsumi H, Tateishi Y, Yamamura S, Tsunematsu R, Matsumoto M, Nakayama KI.

Mol Cell Biol. 2012 Feb;32(3):590-605. doi: 10.1128/MCB.06570-11.

5.

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.

Bhaskaran S, Dileep KV, Deepa SS, Sadasivan C, Klausner M, Krishnegowda NK, Tekmal RR, VandeBerg JL, Nair HB.

Mol Cancer Ther. 2013 Apr;12(4):361-72. doi: 10.1158/1535-7163.MCT-12-0965.

6.

alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.

Hu R, Aplin AE.

Pigment Cell Melanoma Res. 2010 Apr;23(2):201-9. doi: 10.1111/j.1755-148X.2010.00668.x.

7.

Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.

Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA.

Mol Cell. 2006 Nov 3;24(3):355-66.

8.

The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation.

Vaites LP, Lee EK, Lian Z, Barbash O, Roy D, Wasik M, Klein-Szanto AJ, Rustgi AK, Diehl JA.

Mol Cell Biol. 2011 Nov;31(22):4513-23. doi: 10.1128/MCB.05733-11.

9.

Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.

Xie X, Koh JY, Price S, White E, Mehnert JM.

Cancer Discov. 2015 Apr;5(4):410-23. doi: 10.1158/2159-8290.CD-14-1473.

10.

A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation.

Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O.

PLoS One. 2006 Dec 27;1:e128.

11.

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma.

Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fässler R, Bosserhoff AK.

J Exp Med. 2009 Jan 16;206(1):221-32. doi: 10.1084/jem.20082044.

12.

Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.

Williams RT, Barnhill LM, Kuo HH, Lin WD, Batova A, Yu AL, Diccianni MB.

PLoS One. 2014 Feb 5;9(2):e88219. doi: 10.1371/journal.pone.0088219.

13.
14.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025.

15.

Effect of ursolic acid on MAPK in cyclin D1 signaling and RING-type E3 ligase (SCF E3s) in two endometrial cancer cell lines.

Achiwa Y, Hasegawa K, Udagawa Y.

Nutr Cancer. 2013;65(7):1026-33. doi: 10.1080/01635581.2013.810292.

PMID:
24083669
16.

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.

Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA, Curry JL.

Hum Pathol. 2016 Apr;50:79-89. doi: 10.1016/j.humpath.2015.12.003.

PMID:
26997441
17.

Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.

Zhao Y, Zhang Y, Yang Z, Li A, Dong J.

Biochem Biophys Res Commun. 2008 Jun 6;370(3):509-13. doi: 10.1016/j.bbrc.2008.03.148.

PMID:
18402768
18.

cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Cohen JD, Tham KY, Mastrandrea NJ, Gallegos AC, Monks TJ, Lau SS.

Toxicol Sci. 2011 Aug;122(2):361-71. doi: 10.1093/toxsci/kfr118.

19.

Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Luo C, Sheng J, Hu MG, Haluska FG, Cui R, Xu Z, Tsichlis PN, Hu GF, Hinds PW.

Cancer Res. 2013 Jul 15;73(14):4337-48. doi: 10.1158/0008-5472.CAN-12-4454.

20.

SCF(Fbx4/alphaB-crystallin) E3 ligase: when one is not enough.

Barbash O, Diehl JA.

Cell Cycle. 2008 Oct;7(19):2983-6. Review.

PMID:
18818515
Items per page

Supplemental Content

Support Center